Full-Time

Associate Director

Accounting

Updated on 11/21/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$183k - $194kAnnually

Senior

San Carlos, CA, USA

Requires onsite presence in San Carlos, California for three days per week.

Category
Financial Accounting
Management Accounting
Accounting
Required Skills
NetSuite
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s Degree in Finance/ Accounting or equivalent is required; C.P.A and experience at in public accounting, is preferred.
  • 10+ years of experience accounting operations with progressive levels of responsibility is required.
  • 4+ years of experience supervising, planning and directing the work of multiple direct reports is required.
  • Experience in accounting roles with varying degrees of complexity.
  • Superior computer skills (Microsoft Office including Excel, Word and PowerPoint).
  • NetSuite experience a plus.
  • Experience with Netsuite, ADP, SAP Concur and other accounting and reporting tools is a plus.
  • Excellent oral and written communication skills.
  • Strong problem-solving skills.
  • Excellent attention to details.
  • Self-motivated and self-directed.
  • Public company experience is preferred.
  • Ability to work onsite 3 days per week required; and more often based on business needs.
Responsibilities
  • Supervising a team of at least two (2) direct reports, primarily leading accounting operations and/or shared services that support the business.
  • Lead functions under management in identifying, reviewing/verifying, analysis and implementing process improvement opportunities including impact and risk assessments, status reporting and change management.
  • Ensure proper reviews and issues are resolved timely, that our processes are compliant with established SOX controls and that we ascertain the accuracy and completeness of the underlying transactions.
  • Collaborates well with the extended finance team to ensure adherence to a timely close and reporting process, timely responses to internal/external audit requests and overall execution of team objectives.
  • Involvement in special projects, system implementations, upgrades, integrations or process improvements, as needed.
  • Develop and manage a high functioning, efficient and responsive team.
  • Own accruals for certain vendors, including management of accrual, review of open purchase orders and invoices, and review of reconciliations and latest estimate processes.
  • Collaborate closely with internal and external teams, as well as FP&A to understand scope to inform the accrual process and report accurately and timely.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

23%

1 year growth

61%

2 year growth

132%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?